Bimonthly, treat-and-extend, and pro re nata ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial
Effect of Adjuvant Topical Dorzolamide-Timolol vs. Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Intravitreal Combined Aflibercept + Anti-PDGFRβ for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
TANDEM TRIAL: A factorial randomized controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands
HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration 2020
Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
